Sunday, 7 February 2010

Virus-free Technique Easily Makes Pluripotent Stem Cells

Virus-free Technique Easily Makes Pluripotent Stem Cells
Sunday, 07 February 2010

Tiny circles of DNA are the key to a new and easier way to transform stem cells from human fat into induced pluripotent stem cells for use in regenerative medicine, say scientists at the
Stanford University School of Medicine. Unlike other commonly used techniques, the method, which is based on standard molecular biology practices, does not use viruses to introduce genes into the cells or permanently alter a cell's genome.

It is the first example of reprogramming adult cells to pluripotency in this manner, and is hailed by the researchers as a major step toward the use of such cells in humans. They hope that the ease of the technique and its relative safety will smooth its way through the necessary FDA approval process.

"This technique is not only safer, it's relatively simple," said Stanford surgery professor
Michael Longaker, MD, and co-author of the paper.

"It will be a relatively straightforward process for labs around the world to begin using this technique. We are moving toward clinically applicable regenerative medicine."

The Stanford researchers used the so-called mini-circles - rings of DNA about one-half the size of those usually used to reprogram cell - to induce pluripotency in stem cells from human fat. Pluripotent cells can then be induced to become many different specialized cell types. Although the researchers plan to first use these cells to better understand - and perhaps one day treat-human heart disease, induced pluripotent stem cells, or iPS cells, are a starting point for research on many human diseases.

"Imagine doing a fat or skin biopsy from a member of a family with heart problems, reprogramming the cells to pluripotency and then making cardiac cells to study in a laboratory dish," said cardiologist
Joseph Wu, MD, PhD.

"This would be much easier and less invasive than taking cell samples from a patient's heart." Wu is the senior author of the research, which will be published online Feb. 7 in Nature Methods. Research assistant Fangjun Jia, PhD is the lead author of the work.

Longaker is the deputy director of Stanford's Institute for Stem Cell Biology and Regenerative Medicine and director of children's surgical research at Lucile Packard Children's Hospital. Wu is an assistant professor of cardiology and of radiology, and a member of Stanford's Cardiovascular Institute. A third author, Mark Kay, MD, PhD, is the Dennis Farrey Family Professor in Pediatrics and professor of genetics.

The finding brings together disparate areas of Stanford research. Kay's laboratory invented the mini-circles several years ago in a quest to develop suitable gene therapy techniques. At the same time, Longaker was discovering the unusual prevalence and developmental flexibility of stem cells from human fat. Meanwhile, Wu was searching for ways to create patient-specific cell lines to study some of the common, yet devastating, heart problems he was seeing in the clinic.

"About three years ago Mark gave a talk and I asked him if we could use mini-circles for cardiac gene therapy," said Wu.

"And then it clicked for me, that we should also be able to use them for non-viral reprogramming of adult cells."

The mini-circle reprogramming vector works so well because it is made of only the four genes needed to reprogram the cells (plus a gene for a green fluorescent protein to track mini-circle -containing cells). Unlike the larger, more commonly used DNA circles called plasmids, the mini-circles contain no bacterial DNA, meaning that the cells containing the mini-circles are less likely than plasmids to be perceived as foreign by the body. The expression of mini-circle genes is also more robust, and the smaller size of the mini-circles allows them to enter the cells more easily than the larger plasmids. Finally, because they do not replicate they are naturally lost as the cells divide, rather than hanging around to potentially muck up any subsequent therapeutic applications.

The researchers chose to test the reprogramming efficiency of the mini-circles in stem cells from human fat because previous work in Wu and Longaker's lab has shown that the cells are numerous, easy to isolate and amenable to the iPS transformation, probably because of the naturally higher levels of expression of some reprogramming genes. They found that about 10.8 percent of the stem cells took up the mini-circles and expressed the green fluorescent protein, or GFP, versus about 2.7 percent of cells treated with a more traditional DNA plasmid.

When the researchers isolated the GFP-expressing cells and grew them in a laboratory dish, they found that the mini-circles were gradually lost over a period of four weeks. To be sure the cells got a good dose of the genes, they reapplied the mini-circles at days four and six. After 14 to 16 days, they began to observe clusters of cells resembling embryonic stem cell colonies - some of which no longer expressed GFP.

They isolated these GFP-free clusters and found that they exhibited all of the hallmarks of induced pluripotent cells: they expressed embryonic stem cell genes, they had similar patterns of DNA methylation, they could become multiple types of cells and they could form tumours called teratomas when injected under the skin of laboratory mice. They also confirmed that the mini-circles had truly been lost and had not integrated into the stem cells' DNA.

Altogether, the researchers were able to make 22 new iPS cell lines from adult human adipose stem cells and adult human fibroblasts. Although the overall reprogramming efficiency of the mini-circle method is lower than that of methods using viral vectors to introduce the genes (about 0.005 percent vs. about 0.01-0.05 percent, respectively), it still surpasses that of using conventional bacterial-based plasmids. Furthermore, stem cells from fat, and, for that matter, fat itself, are so prevalent that a slight reduction in efficiency should be easily overcome.

"This is a great example of collaboration," said Longaker.

"This discovery represents research from four different departments: paediatrics, surgery, cardiology and radiology. We were all doing our own things, and it wasn't until we focused on cross-applications of our research that we realized the potential."

"We knew mini-circles worked better than plasmids for gene therapy," agreed Kay, "but it wasn't until I started talking to stem cell people like Joe and Mike that we started thinking of using mini-circles for this purpose. Now it's kind of like 'why didn't we think of this sooner?'"

Reference:
A non-viral mini-circle vector for deriving human iPS cells
Fangjun Jia, Kitchener D Wilson, Ning Sun, Deepak M Gupta, Mei Huang, Zongjin Li, Nicholas J Panetta, Zhi Ying Chen, Robert C Robbins, Mark A Kay, Michael T Longaker & Joseph C Wu
Nature Methods Published online: 07 February 2010, doi:10.1038/nmeth.1426

.........


ZenMaster


For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/

Gene Improves Quality of Reprogrammed Stem Cells

Provides 'a better inkling of what we might aim for before differentiating iPS cells to clinically useful cell types'
Sunday, 07 February 2010

In the 7 Feb. 2010 issue of the journal Nature, scientists at the
Genome Institute of Singapore (GIS), report that a genetic molecule, called Tbx3, which is crucial for many aspects of early developmental processes in mammals, significantly improves the quality of stem cells that have been reprogrammed from differentiated cells.

Stem cells reprogrammed from differentiated cells are known as induced pluripotent stem cells or iPS cells.

By adding Tbx3 to the existing reprogramming cocktail, GIS scientists successfully produced iPS cells that were much more efficient in recapitulating the entire developmental process.

The capability of iPS cells for germ-line transmission represents one of the most stringent tests of their ESC-like quality. This test requires that iPS cells contribute to the formation of germ cells that are responsible for propagating the next generation of offspring.

"This represents a significant milestone in raising the current standards of iPS cell research. With this new knowledge, we are now able to generate iPS cells which are, or approach, the true equivalent of ESCs," said
Lim Bing, M.D., Ph.D., lead author of the Nature paper and Senior Group Leader at GIS, one of the research institutes of Singapore's A*STAR (Agency for Science, Technology and Research).

"When applied to the area of cell therapy-based medicine, we have a better inkling of what we might aim for before differentiating iPS cells to clinically useful cell types. The finding also adds to our insight into the fascinatingly, unchartered but rapidly moving field of reprogramming," Lim added.

George Q. Daley, M.D., Ph.D., Director, Stem Cell Transplantation Program, HHMI/Children's Hospital Boston, Harvard Medical School, added:

"This paper highlights the rapid progress towards optimized reprogramming strategies. The Singapore group has made an important advance in the production of high quality iPS cells. I would like to congratulate them on this important contribution."

Embryonic stem cells (ESCs) are undifferentiated master stem cells that are developmentally important because they give rise to all other differentiated cell types in the human body. It has been shown that with the introduction of a few genetic factors into differentiated cells, these master stem (undifferentiated) cells can be re-created through a process known as reprogramming into iPS cells.

Converting adult cells to embryonic cells such as iPS cells represents one of the most astounding breakthrough technologies in biological research. These cells look and behave like normal embryonic stem cells (ESCs) that can generate all other tissue types. Hence the great excitement over iPS potential impact on tissue regeneration and development of therapeutics.

Previous studies have demonstrated how scientists can make iPS cells by using different cocktails of genetic factors, as well as improve this efficiency via the addition of chemical supplements. However, not all iPS cells generated with different cocktails resemble true ESCs; that is, the quality of the iPS cells is highly varied.

"The ability to produce iPS cells has the potential to accelerate advances in human medicine. To achieve this objective, it is important to establish iPS cells that most closely resemble authentic embryo-derived pluripotent stem cells," said Azim Surani, Ph.D., Professor of Physiology and Reproduction at the Wellcome Trust /Cancer Research UK Gurdon Institute, University of Cambridge.

"The new study by Bing Lim and colleagues shows that the inclusion of Tbx3 as one of the reprogramming factors significantly improves the quality of iPS cells. These iPS cells were superior since viable adults composed entirely of these iPS cells could be generated," said Surani.

"These iPS cells also showed superior ability for contribution and transmission through the germ line, which is one of the critical criteria for assessing the quality of iPS cells."

Reference:
Tbx3 improves the germ-line competency of induced pluripotent stem cells
Jianyong Han, Ping Yuan, Henry Yang, Jinqiu Zhang, Junliang Tay, Boon Seng Soh, Pin Li, Siew Lan Lim, Suying Cao, Yuriy L. Orlov, Thomas Lufkin, Huck-Hui Ng, Wai-Leong Tam, Bing Lim
Nature advance online publication 7 February 2010,
doi:10.1038/nature08735
.........


ZenMaster


For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/

Wednesday, 3 February 2010

Scientists Map Epigenome of Human Stem Cells during Development

Billions of data points provide big picture of 'human epigenome' during critical developmental window
Wednesday, 03 February 2010

Scientists at the
Genome Institute of Singapore (GIS) and the Scripps Research Institute (TSRI) led an international effort to build a map that shows in detail how the human genome is modified during embryonic development.

This detailed mapping is a significant move towards the success of targeted differentiation of stem cells into specific organs, which is a crucial consideration for stem cell therapy.

The study was published in the journal Genome Research on Feb. 4, 2010.

Chia-Lin Wei, Ph.D., senior author and Senior Group Leader at the GIS, a biomedical research institute of Singapore's Agency for Science, Technology and Research (A*STAR), said:

"In this study, we mapped a major component of the epigenome, DNA methylation, for the entire sequence of human DNA, and went further by comparing three types of cells that represented three stages of human development: human embryonic stem cells, human embryonic stem cells that were differentiated into skin-like cells, and cells derived from skin. With these comprehensive DNA methylome maps, scientists now have a blueprint of key epigenetic signatures associated with differentiation."

"The cells in our bodies have the same DNA sequence," said TSRI Professor Jeanne Loring, Ph.D., who is a co-senior author of the paper along with Isidore Rigoutsos of IBM Thomas J. Watson Research Center and Chia-Lin Wei of GIS.

"Epigenetics is the process that determines what parts of the genome are active in different cell types, making a nerve cell, for example, different from a muscle cell."

DNA methylation causes specific subunits of DNA to be chemically modified, which controls which areas of the genome are active and which ones are dormant. DNA methylation is critical to the process in which embryonic cells change from "pluripotent stem cells," which have the ability to turn into hundreds of cell types, to "differentiated cells," distinct types of cells that make up different parts of the body, such as the skin, hair, nerves, etc..

In reviewing the data produced by the study – information on the methylation of three billion base pairs of DNA – the scientists were able to identify previously unknown patterns of DNA methylation. They identified cases in which DNA methylation appeared to enhance, rather than repress, the activity of the surrounding DNA, and found evidence to suggest a role for DNA methylation in the regulation of mRNA splicing.

"We produced a very large amount of data," said Loring.

"But it actually simplifies the picture. We identified patterns of many genes that are methylated or de-methylated during differentiation. This will allow us to better understand the exquisitely choreographed changes that cells undergo as they develop into different cell types."

Louise Laurent of TSRI and the University of California, San Diego, one of the first authors of the study, added:

"The data are publicly available, and we are looking forward to learning what other scientists discover from using this information for their own studies on individual genes, embryonic development, and stem cells."

"This is definitely an exciting finding in the field of stem cell research," added co-first author Eleanor Wong, who is a graduate student from the GIS in Dr Wei's lab.

"Using this knowledge, scientists can now survey different cell types and developmental pathways, identify the genes affected, and characterize the functions of these genes in the process of differentiation. It's all very exciting!"

Reference:
Dynamic changes in the human methylome during differentiation
Louise Laurent, Eleanor Wong, Guoliang Li, Tien Huynh, Aristotelis Tsirigos, Chin Thing Ong, Hwee Meng Low, Ken Wing Kin Sung, Isidore Rigoutsos, Jeanne Loring and Chia-Lin Wei
Genome Research, Feb. 4, 2010 online issue.
.........


ZenMaster


For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/

Human Embryonic Stem Cells Arrests Acute Lung Injury in Mice

Human Embryonic Stem Cells Arrests Acute Lung Injury in Mice
Wednesday, 03 February 2010

A new study by Rick Wetsel, Ph.D., left and Dachun Wang, M.D., of the University of Texas Health Science Center at Houston, explores the potential use of transplantable lung cells derived from human embryonic stem cells to treat respiratory disease. Credit: The University of Texas Health Science Center at Houston.Stem cell researchers exploring a new approach for the care of respiratory diseases report that an experimental treatment involving transplantable lung cells was associated with improved outcomes in tests on mice with acute lung injury. The lung cells were derived from human embryonic stem cells (hESCs). Findings by investigators at the
University of Texas Health Science Center at Houston are scheduled to appear in the March issue of Molecular Therapy.

Mice receiving the transplantable lung cells lived longer, sustained less scarring in their lungs and had normal amounts of oxygen in their blood, said
Rick Wetsel, Ph.D., the study's senior author and a professor in the university's Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM).

"Respiratory diseases are a major cause of mortality and morbidity worldwide," wrote Wetsel and his colleagues in the paper.

"Current treatments offer no prospect of cure or disease reversal. Transplantation of pulmonary progenitor cells derived from human embryonic stem cells may provide a novel approach to regenerate endogenous lung cells destroyed by injury and disease."

Giuseppe N. Colasurdo, M.D., dean of The University of Texas Medical School at Houston and physician-in-chief at Children's Memorial Hermann Hospital, said:

"This research work will provide a useful model for studying the pathogenesis and treatment of a variety of lung disorders. I am confident future studies will advance our knowledge on the cellular mechanisms responsible for the improvement observed in the study."

Colasurdo, who specializes in lung disorders in children and infants, said a better understanding of the basic mechanisms involved in the healing phase of lung diseases is critical to the development of treatments.


"These are diseases involving a variety of cells and cell products," he said.

Much human embryonic stem cell research is focused on conditions like lung injury in which the body has difficulty healing itself. Because these early stage cells can mature into many different cell types, they are being explored as a way to replace or repair missing or damaged tissue. These cells also divide rapidly providing researchers with a large supply of cells.

Scientists compared the outcomes of mice with damaged lungs receiving the treatment to those not receiving the treatment.

Researchers reported that the experimental stem cell treatment "not only prevented or reversed visual hallmarks of pulmonary injury, but also restored near normal lung function to mice." Lung cells can be damaged by exposure to pollution and disease agents.

Wetsel and his colleague Dachun Wang, M.D., an IMM instructor, used a genetic selection procedure they created to generate a type of lung cell known as alveolar epithelial type II. These cells secrete surfactant, a substance that keeps the lung inflated, and can also turn into another important lung cell that regulates the transfer of oxygen into the blood and the removal of carbon dioxide. The human embryonic stem cells used in this research were approved by the National Institutes of Health (NIH) for study.

Wetsel called the results "promising" but added that additional tests in other animal models and eventually humans will be needed before these cell transplants can be used to treat respiratory diseases.

The scientists used mice with weakened immune systems to reduce the possibility that the human cells would be rejected. Should research proceed to the clinical trial stage, there are at least two ways to address rejection issues, Wetsel said. Patients could be treated with immunosuppressive drugs. Scientists may also be able to take one of the patient's own skin cells and convert it into "induced pluripotent stem cells" or iPS cells, which are believed to have many of the same capabilities as human embryonic stem cells.

Reference:
Transplantation of Human Embryonic Stem Cell-Derived Alveolar Epithelial Type II Cells Abrogates Acute Lung Injury in Mice
Dachun Wang, John E Morales, Daniel G Calame, Joseph L Alcorn and Rick A Wetsel

Molecular Therapy (2010);
doi:10.1038/mt.2009.317
.........


ZenMaster


For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/

CellNEWSBlog featured on Reuters and FOX News!